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Abstract
Lymphocytic infiltration in the lamina propria (LP), which is primarily composed of CD4+ Th1 cells and plasma cells, and
increased numbers of intraepithelial lymphocytes (IELs), is a characteristic finding in active celiac disease (CD). Signals for
this selective cell recruitment have not been fully established. CXCR3 and its ligands, particularly CXCL10, have been
suggested to be one of the most relevant pathways in the attraction of cells into inflamed tissues. In addition, CXCR3 is
characteristically expressed by Th1 cells. The aim of this work was to investigate the participation of the chemokine CXCL10/
CXCR3 axis in CD pathogenesis. A higher concentration of CXCL10 was found in the serum of untreated CD patients. The
mRNA levels of CXCL10 and CXCL11 but not CXCL9 were significantly higher in duodenal biopsies from untreated CD
patients compared with non-CD controls or treated patients. The results demonstrate that CXCL10 is abundantly produced
in untreated CD and reduced in treated patients, and the expression of CXCL10 was found to be correlated with the IFNc
levels in the tissue. Plasma cells and enterocytes were identified as CXCL10-producing cells. Moreover, the CXCL10
expression in intestinal tissues was upregulated by poly I:C and IL-15. IELs, LP T lymphocytes, and plasma cells, which
infiltrate the intestinal mucosa in untreated CD, express CXCR3. The CXCR3/CXCL10 signalling axis is overactivated in the
small intestinal mucosa in untreated patients, and this finding explains the specific recruitment of the major cell populations
that infiltrate the epithelium and the LP in CD.
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Introduction
Celiac disease (CD) is an immune-mediated enteropathy caused
by ingested gluten in genetically susceptible individuals. Active CD
is characterised by histological changes in the small intestinal
mucosa, such as villous atrophy, crypt hyperplasia, infiltration of
lymphocytes, primarily T cells and plasma cells, into the lamina
propria (LP), and increased intraepithelial lymphocytes (IELs).
Mechanisms of both innate and adaptive immunity participate in
intestinal mucosal damage, which involves disruption of tight
junction integrity and the production of proinflammatory cyto-
kines, during the early phase of CD. Direct damage to epithelial
cells is considered to be primarily caused by the infiltration and
activation of IELs, and IL-15 is hypothesised to play a major role
by favouring the survival and cytotoxicity of these cells [1]. It has
been clearly established that gluten peptides activate HLA-DQ2-
or DQ8-restricted-CD4+ T lymphocytes. These T cells belong to
the Th1 subset and, upon activation, produce high amounts of
IFNc [2]. This abundance of LP Th1 cells is largely responsible for
the maintenance of an appropriate environment for the cytotoxic
activity of IELs and for antibody production at the duodenal
mucosa in untreated CD patients [3].
Antigen-loaded dendritic cells migrate out of the LP to the
mesenteric lymph nodes, where these dendritic cells activate and
differentiate naı¨ve CD4+ T cells into Th1 cells. Upon differenti-
ation, Th1 cells circulate in the peripheral blood and finally arrive
into the LP under guidance by MadCAM1/a4b7 and CCL25/
CCR9. These pairs of ligand/receptors are involved in the
selective migration of lymphocytes into the intestinal mucosa
under homeostatic conditions [4]. However, during an inflamma-
tory process, cell recruitment is preferentially guided by other
pathways. CXCR3 and its ligands have been suggested to be one
of the most relevant chemokine axes that promote the arrival of
cells into inflamed tissues [5]. This axis is known to be active in
different chronic inflammatory processes, such as rheumatoid
arthritis [6,7] and inflammatory bowel diseases [8–10]. CXCR3 is
expressed in T and B lymphocytes, NK cells, eosinophils, and
monocytes [11]. In particular, CD4+ Th1 cells characteristically
express CXCR3 [5,12,13]. This receptor interacts with three
ligands: CXCL9, CXCL10, and CXCL11. These chemokines
have non-redundant biological roles. All of these chemokines are
inducible by IFNc; however, their pattern of expression in
different tissues has not been fully elucidated [14]. Of the CXCR3
ligands, CXCL10 shows a strong association with autoimmunity
[6,15,16]. CXCL10 is produced by CD4+ T cells, NK and NKT
cells, monocytes, dendritic cells, fibroblasts, endothelial, and
epithelial cells [7,17]. In addition to IFNc, other stimuli, such as
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TNFa and type I IFN, induce CXCL10 expression and thereby
amplify the inflammatory cascade [14].
Although the infiltration of lymphocytes into the LP and
increased IELs are hallmarks in CD enteropathy, the mechanism
underlying specific cell recruitment has not been studied. Because
Th1 cells characteristically express CXCR3 and certainly take part
in the damage mechanisms that cause severe enteropathy, the aim
of this work was to assess the role of the CXCL10/CXCR3 axis in
lymphocytic recruitment in active CD. In this study, we
demonstrate the increased production of CXCL10 in the
epithelium and LP, primarily by enterocytes and plasma cells,
respectively, in the intestinal mucosa of untreated CD patients.
CXCL10 was induced in the duodenal tissue by innate stimuli. We
also showed the expression of CXCR3 in IELs and in LP T
lymphocytes and plasma cells.
Patients and Methods
Samples
Duodenal biopsies were obtained from paediatric and adult
patients during routine procedures to diagnose celiac disease. In
total, 26 untreated celiac patients (six adults and 20 children) and
six treated CD patients (three adults and three children) were
included in the gene expression analysis. CD diagnosis was
achieved by histological examination, serological analysis, and the
evaluation of clinical presentation. Patients on a gluten-free diet
(GFD) presented histological recovery and negative serological
markers for CD. Twenty-five biopsies from non-celiac individuals
(nine adults and 16 children) were also included in this study. All of
the individuals who suffered from other gastrointestinal conditions,
primarily dyspepsia, presented negative CD serology and normal
duodenal histology. The samples were stabilised using RNAlater
(Ambion, cat AM7020) and stored at 280uC until processing for
gene expression analysis. An additional biopsy was obtained,
formalin fixed and embedded in paraffin for immunofluorescence
studies. For some experiments, two biopsy pieces were collected
for in vitro stimulation, as described below. In total, 23 untreated
celiac patients and 32 non-CD controls were included in this assay.
Serum samples were collected from 26 celiac patients at the
time of diagnosis (15 adults and 11 children), nine treated CD
patients (six adults and three children), and 21 control subjects (14
adults and seven children). Because there was no difference
between the samples obtained from paediatric and adult
populations, the data from the samples from both populations
were depicted together in all of the analyses that were performed
in this study.
Ethics Statements
The participants or their guardians provided written informed
consent to participate in this study. The present study was
approved by the Ethical Committees of the HIGA San Martin and
Sor Maria Ludovica Hospitals from La Plata, Buenos Aires,
Argentina.
Gene Expression Analysis
The total RNA was isolated from whole biopsy samples using an
RNA Spin Mini kit (GE Healthcare, cat 25-0500-72). The RNA
quality and quantity were assessed through conventional spectro-
photometric methods. Reverse transcription was performed using
1 mg of the total RNA. MML-V polymerase and random primers
were obtained from Molecular Probes Inc., Invitrogen (Carlsbad,
CA, USA). Real-time PCR was performed using an IQ-Cycler
(Bio-Rad) with the SYBR Green Supermix (Invitrogen, cat 11761-
100). b-actin was used as the housekeeping gene. Relative
quantitation of gene expression was calculated using the accurate
Ct (threshold cycle) method [18]. Table 1 shows the primer pairs
used in this work. The running protocol for the detection of
CXCL9, CXCL10, CXCL11, and CXCR3 was the following:
95uC for 10 min and 50 cycles of 60uC for 15 s, 72uC for 45 s, and
95uC for 15 s. For IFNc, TNFa, and IFNb, the protocol was the
following: 95uC 10 min and 50 cycles of 62uC for 1 min and 95uC
15 s.
Immunofluorescence Confocal Microscopy
Paraffin-embedded duodenal biopsies from adult celiac patients,
including both treated and active patients, and controls were used.
Table 1. Primer pairs used for real-time PCR
(59–39orientation).
GENE Forward Primer Reverse Primer
b-actin ATGGGTCAGAAGTCCTATGTG CTTCATGAGGTAGTCAGTCA-
GGTC
CXCL9 CCAAGGGACTATCCACCT-
ACAATC
GGTTTAGACATGTTTGAACTC-
CATTC
CXCL10 CTGACTCTAAGTGGCATTCA-
AGGA
CAATGATCTCAACACGTGGA-
CAA
CXCL11 GGGTACATTATGGAGGCTT-
TCTCA
GAGGACGCTGTCTTTGCATAGG
CXCR3 AGCTTTGACCGCTACCTGAA TGTGGGAAGTTGTATTGGCA
IFNc GCAGAGCCAAATTGTCTCCT ATGCTCTTCGACCTCGAAAC
TNFa CTCAGCCTCTTCTCCTTCCT TTCGAGAAGATGATCTGACTGC
IFNb TGGGAGGCTTGAATACTGC-
CTCAA
TCTCATAGATGGTCAATGCG-
GCGT
doi:10.1371/journal.pone.0089068.t001
Figure 1. Serum levels of CXCL10. The CXCL10 concentrations in
serum samples from 21 non-celiac individuals, 26 untreated celiac
patients, and nine CD patients on a GFD were assessed by quantitative
ELISA. The untreated CD patients presented higher levels of CXCL10
than the controls (unpaired t test; p = 0.0007). The treated celiac
patients presented lower levels of CXCL10 than the untreated patients,
although the difference was not statistically significant.
doi:10.1371/journal.pone.0089068.g001
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Sections of 5 mm were rehydrated and treated with Antigen
Retrieval Citra Plus Solution (BioGenex, cat HK080-9K). All of
the sections were blocked with goat serum. For CXCR3 staining,
the sections were incubated with 15 mg/ml mouse anti-human
CXCR3 antibody (R&D Systems, cat MAB160) and then with a
1:200 dilution of Alexa Fluor 488-conjugated F(ab’)2 fragment of
goat anti-mouse IgG (H+L) antibody (Invitrogen, cat A11020). For
CXCL10 single staining, the samples were incubated with a 1:50
dilution of polyclonal rabbit anti-human CXCL10 (IP-10)
antibody (Santa Cruz, cat sc-28877) and then with a 1:200
dilution of Alexa Fluor 488-conjugated goat anti-rabbit IgG (H+L)
(Invitrogen, cat A11008). All of the antibodies were incubated for
one h, and the samples were washed in PBS supplemented with
0.1% Tween-20 between each incubation step.
In the double staining protocols, the samples were first
incubated with CXCL10 primary antibody and then with a
1:200 dilution of Alexa Fluor 647-conjugated goat anti-rabbit IgG
antibody (H+L) (Invitrogen, cat A21246). Mouse anti-human CD3
(DBS, cat Mob112-05), mouse anti-human CD138 (DAKO, cat
M7228), or mouse anti-human HAM56 (Genetex, GTX72010)
antibodies were used at dilutions of 1:10, 1:25, and 1:50,
respectively, for overnight incubations. Alexa Fluor 488-conjugat-
ed goat anti-mouse antibody was used as a secondary antibody for
these markers. The nuclei were stained with propidium iodide
(1 mg/ml) for 15 min (Sigma, cat P4170). The samples were
mounted using fluorescent mounting medium (DakoCytomation,
cat S3023) and visualised in a TCS SP5 Leica confocal
microscope. The images were obtained using the Leica LAS AF
software.
Counting of CXCR3+ Cells
Duodenal biopsies from six adult celiac patients, nine adult
controls, and six treated patients were stained for CXCR3 as
previously described. The nuclei were stained with DAPI (Sigma,
cat D8417), and the samples were visualised using a Nikon Eclipse
Ti fluorescence microscope with an X-Cites Series 120 Q light
source. The images were obtained with a Nikon Digital Sight DS
Ri1 camera using the Nis-Elements software, and the cells were
then counted using the Image J software, which was properly
calibrated for measuring the areas. The LP areas were drawn over
the entire histological section, and the average positive cells were
then counted in an area of 150,000 mm2. The surface epithelium,
villi, and crypts were excluded. The cells counts were performed
blindly by the same investigator.
Figure 2. CXCL9, CXCL10, and CXCL11 mRNA levels in the duodenum. a. The mRNA expression levels of CXCR3 ligands were determined by
real-time PCR. Duodenal biopsies from celiac individuals at the time of diagnosis (n = 26), celiac individuals on a GFD (n = 6), and non-CD controls
(n = 25) were included. The untreated celiac patients expressed significantly higher levels of CXCL10 and CXCL11 than the treated patients (p = 0.0436
and p = 0.0160, respectively) and controls (p = 0.0002 and p,0.0001, respectively). There was no difference in the CXCL9 mRNA levels between the
groups. The results are shown as relative units in reference with the levels of the housekeeping gene b-actin. An unpaired t-test was used to assess
the significance of the differences. b. The correlation between the mRNA levels of CXCL10 and the mRNA levels of CXCL11 in duodenal samples from
CD patients (black circles) and non-CD controls (white circles) was analysed. The CXCL10 and CXCL11 expression levels were correlated significantly in
untreated CD patients (r = 0.7463, p,0.0001) and in non-CD controls (r = 0.6690, p = 0.0003).
doi:10.1371/journal.pone.0089068.g002
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Determination of CXCL10 in Serum
The CXCL10 concentration in the serum samples was
measured using a commercially available enzyme-linked immu-
nosorbent assay (ELISA kit Human IP-10 (CXCL10), cat
KAC2361, Invitrogen, Camarillo, USA) following the manufac-
turer’s instructions. Blood samples were collected from paediatric
and adult patients during the routine procedure to diagnose celiac
disease. The serum samples were stored at 280uC until use in
subsequent assays. Each sample with a high CXCL10 concentra-
tion was diluted 1:2 and/or 1:10 prior testing.
In vitro Stimulation of Duodenal Tissue
Two duodenum biopsy specimens were collected from the same
patient during an upper-gastrointestinal endoscopy and immedi-
ately processed. RPMI medium supplemented with 62.4 mg/ml
penicillin (Bago´ Laboratories), 100 mg/ml streptomycin (Bago´
Laboratories), 0.5 g/l gentamicin, and 10% foetal calf serum
(Gibco) was used. The samples were incubated for 3 h at 37uC in
medium alone or in medium supplemented with one of the
following stimuli: 50 ng/ml human recombinant IL-15 (BD
Pharmingen) or 100 mg/ml polyinosinic-polycytidylic acid sodium
salt (poly I:C) (Sigma Aldrich, cat P1530). After culture, the
samples were washed with 0.5 g/l HBSS/gentamicin, and the
total RNA was extracted. Gene expression was analysed as
indicated above.
Flow Cytometry Analysis
Two duodenal biopsies from paediatric CD patients were
collected in ice-chilled RPMI medium and processed further in the
laboratory within 30 min. Preparations of single-cell suspensions
were performed as follows: epithelial cells and IELs were removed
by incubation with 1 mM EDTA in PBS for 30 min with
continuous rotation at 37uC. LP single-cell suspensions were
obtained by digesting the remaining material with DNase I
(Roche) and collagenase (Sigma) for 30 min with rotation at 37uC.
The cell suspension was then filtered through a 40-mm cell strainer
and washed with PBS. The cells were blocked with human serum
Figure 3. Expression of IFNc, IFNb, and TNFa in the duodenum and their correlation with the levels of CXCR3 ligands. a. The mRNA
levels of IFNc, IFNb, and TNFa were determined by real-time PCR in the same set of samples that were previously tested: untreated celiac (n = 26),
patients on a GFD (n = 6), and non-CD controls (n = 25). The IFNc expression levels were significantly higher in the untreated celiac patients compared
with the treated patients (p = 0.0123) and the controls (p,0.0001). The TNFa levels in the untreated celiac patients were lower than those found in
the controls and the treated patients (unpaired t-test; p = 0.0054 and p = 0.0004, respectively). No significant difference was observed in the IFNb
expression levels between these groups. b. The correlation of the CXCL10 expression levels with the IFNc levels in duodenal samples from untreated
CD patients and non-CD controls was analysed. The IFNc levels were positively correlated with the CXCL10 expression level in both untreated celiac
patients (r = 04233, p = 0.0312) and non-CD controls (r = 0.5448, p = 0.0049). Linear regression analysis, Pearson’s coefficient, F-test.
doi:10.1371/journal.pone.0089068.g003
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and stained with labelled antibodies on ice for 15 min. After
incubation, the cells were briefly washed, resuspended in PBS, and
analysed with a FACSCalibur instrument (BD Biosciences). The
data were analysed using the FlowJo 7.6.2 software. The following
antibodies were used (all from BD Pharmingen): APC-conjugated
mouse anti-human CD183 (clone 1C6/CXCR3), FITC-conjugat-
ed mouse anti-human CD3 (clone UCHT1), PE-conjugated
mouse anti-human CD103 (clone Ber-ACT8), PE-conjugated
mouse anti-human CD4 (clone RPA-T4), PE-conjugated mouse
anti-human CD138 (clone MI15), and APC-, FITC-, or PE-
conjugated mouse IgG1 k isotype controls (clone MOPC-21).
Statistical Analysis
The statistical analyses were performed with the Prism v.5.0
software (GraphPad software Inc., La Jolla, CA, USA), and this
software was also used to construct the graphs. Two-tailed P-
values less than 0.05 were considered significant. A comparison of
the expression levels and the positive cell numbers between
subjects, which included active and treated CD patients, was
performed using unpaired t-tests. Correlation analyses were
performed using Pearson’s correlation test. Statistical analysis in
experiments using in vitro stimulated biopsies were evaluated
through paired t-tests.
Results
Serum Levels of CXCL10 are Increased in Untreated CD
Patients
Increased levels of circulating CXCL10 have been detected in
inflammatory processes and autoimmunity [15,19]. However, to
the best of our knowledge, no study has investigated CXCL10
expression in CD patients. To this end, we evaluated the levels of
CXCL10 in serum samples from untreated CD patients, celiac
patients on a gluten-free diet (GFD), and non-celiac controls using
a quantitative ELISA. The concentration of CXCL10 was
significantly higher in untreated CD patients than in non-CD
controls. The levels of CXCL10 in the treated CD group were
lower than those found in untreated patients, although this
difference was not statistically significantly (Figure 1). These
results suggest a link between CXCL10 production and persistent
gluten insult in untreated CD patients.
Figure 4. Overexpression of CXCL10 in the duodenal mucosa of untreated CD patients. A representative immunofluorescence confocal
microscopic analysis of CXCL10 expression in duodenal sections of untreated CD (i) and control subjects (ii) is shown. a. Active CD patients showed a
massive expression of CXCL10 in the entire mucosa, whereas the controls only showed isolated CXCL10+ cells in the LP. CXCL10 is shown in green,
and the nuclei are shown in red. (Magnification, 6306). b. The arrows indicate epithelial cells that produce CXCL10 in the duodenum from an
untreated CD patient (i). In non-CD controls (ii), CXCL10 expression was not observed in the epithelium, and CXCL10+ cells were rarely found in the
LP. (Magnification, 10716).
doi:10.1371/journal.pone.0089068.g004
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Expression of CXCR3 Ligands (CXCL9, CXCL10, and
CXCL11) in Duodenal Mucosa
The mRNA levels of CXCL9, CXCL10, and CXCL11 in
duodenal tissues from untreated and treated CD patients and non-
CD controls were assessed using quantitative PCR (Figure 2a).
Higher levels of CXCL10 and CXCL11 were obtained in the
samples from untreated CD patients than in the control samples.
In addition, patients on a GFD showed levels of these transcripts
that were similar to those found in the controls. In contrast, no
differences were observed in the CXCL9 mRNA levels between
the three groups of samples. These findings indicate that CXCL10
and CXCL11 are actively produced in the duodenum of CD
patients as a result of gluten intake, and a GFD effectively returns
the activation of these genes to basal levels. Note that the mRNA
expression levels of CXCL10 and CXLC11 exhibit a positive
correlation in celiac and in control tissue samples (Figure 2b).
CXCL9 was found to be expressed at markedly lower levels and
independently of the other two chemokines (data not shown).
These results suggest that CXCL10 and CXCL11 are produced as
a consequence of gluten insult and that GFD deactivates the
induction of these chemokines.
Figure 5. Cellular sources of CXCL10 in the small intestinal lamina propria. The cellular sources of CXCL10 in the duodenum were identified
using immunofluorescence confocal microscopy. CD3+ cells were found to be negative for CXCL10 in both CD patients (i) and control subjects (ii).
Numerous CD138+ cells that express CXCL10 were found in the celiac mucosa (iii). Plasma cells expressing CXCL10 were not found in the duodenum
from non-CD controls (iv). HAM56+ cells did not produce CXCL10 in the celiac (v) and in the non-CD control intestinal mucosa (vi). CD3, CD138, and
HAM56 are shown in green, CXCL10 is shown in red, and nuclei are shown in blue. (Magnification, 10716).
doi:10.1371/journal.pone.0089068.g005
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Correlation between the Expression of CXCR3 Ligands
and IFNc, IFNb, and TNFa in the Intestinal Mucosa
The expression of CXCR3 ligands is modulated by different
soluble factors, of which, IFNc, IFNb, and TNFa have a major
influence [14]. To evaluate whether the expression levels of these
inducers correlate with the levels of CXCR3 ligands, we
determined the IFNc, IFNb, and TNFa mRNA levels in duodenal
biopsies from untreated celiac patients, treated celiac patients, and
non-celiac individuals. As expected, the IFNc mRNA level was
significantly increased in untreated patients. In contrast, the TNFa
levels were lower in untreated CD patients compared with treated
celiac patients and controls. However, the biopsies from untreated
CD patients showed higher levels of IFNb mRNA than those of
the treated patients and controls, although the difference was not
statistically significant (Figure 3a).
Remarkably, the CXCL10 mRNA levels were found to
correlate positively with IFNc expression in duodenal tissue from
both CD patients and non-CD controls (Figure 3b), whereas
CXCL10 expression did not correlate with the expression levels of
either IFNb or TNFa (data not shown). In contrast, the
CXCL11 mRNA levels were correlated positively with IFNc
expression in untreated CD patients and with IFNb in the control
subjects (Figure S1). Consequently, CXCL10 showed a strong
correlation with IFNc expression in the intestinal mucosa in
normal tissues and in severe enteropathy.
Overproduction of CXCL10 in the Duodenal Mucosa of
CD Patients
Immunofluorescence confocal microscopy analysis showed a
massive production of CXCL10 in the duodenal mucosa of
untreated CD patients (Figure 4a). Staining for CXCL10
appeared both inside LP cells and in the extracellular matrix. As
a consequence of this overexpression, CXCL10+ cells could not be
properly counted. In contrast, tissue sections from CD patients on
a GFD or from non-CD controls showed CXCL10 staining only
in a few cells in the LP. This massive expression of CXCL10 in the
celiac duodenal mucosa correlates with the high CXCL10
concentration that is observed in the serum of untreated patients.
Therefore, the small intestine of CD patients may be the primary
source of this chemokine under gluten insult and could explain the
high levels of circulating CXCL10 in untreated CD patients.
Remarkably, the confocal microscopy analysis performed in this
study also revealed that enterocytes from duodenal sections of
untreated CD patients but not non-CD controls produce CXCL10
(Figure 4b). Because CD enteropathy is characterised by a
massive infiltration of T lymphocytes and plasma cells, we further
evaluated CD3+ and CD138+ cells as possible sources of CXCL10
production. Double staining for CD3 and CXCL10 showed no
evidence that T lymphocytes are producers of this chemokine in
celiac patients or in controls (Figures 5i and 5ii). As expected,
the small intestine LP from untreated CD patients showed an
increased number of plasma cells (CD138+ cells). Remarkably, a
high proportion of CD138+ cells was found to be CXCL10-
positive (Figure 5iii). In contrast, a lower number of infiltrating
plasma cells, which were all negative for CXCL10, was observed
in the duodenum from non-CD controls (Figure 5iv). The
analysis of macrophages as putative CXCL10 producers revealed
no evidence of HAM56+ CXCL10+ cells in the duodenal mucosa
from celiac patients or controls (Figures 5v and 5vi).
Altogether, these observations suggest that plasma cells are the
main source of CXCL10 in the duodenum of untreated CD
Figure 6. Induction of CXCL10 by IL-15 and poly I:C in the small intestine. Biopsies from celiac patients and non-CD controls were incubated
for 3 h in the presence of IL-15 (a) or Poly I:C (b). A second biopsy from each patient was cultured with medium (NS). In non-CD controls, both IL-15
and poly I:C induced CXCL10 mRNA expression (p = 0.0100 and p = 0.0058, respectively; paired t-test). No significant changes were observed in the
untreated CD group.
doi:10.1371/journal.pone.0089068.g006
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Figure 7. Infiltration of CXCR3+ cells in the lamina propria of small intestine mucosa. a. Confocal immunofluorescence for CXCR3 was
performed in sections of duodenal biopsies from controls (i), untreated celiac patients (ii), and treated celiac patients (iii). CXCR3 is shown in green,
and nuclei are shown in red. Untreated celiac patients showed a higher number of positive cells infiltrating the LP. (Magnification, 6306). b. The
number of CXCR3+ cells in the LP was higher in the duodenal mucosa of untreated celiac patients (n = 9) compared with control individuals (n = 6)
and treated patients (n = 5) (unpaired t-test; p = 0.0089 and p = 0.0055, respectively). The positive cells in LP regions from sections of duodenal
biopsies were counted using immunofluorescence microscopy. c. Representative flow cytometric analysis from the LP compartment of a duodenal
sample of an untreated CD patient showing plasma cells (CD138+) that express CXCR3. d. Representative flow cytometric analysis from the LP
compartment of a duodenal sample of an untreated CD patient showing LP lymphocytes (CD3+ or CD4+) that express CXCR3.
doi:10.1371/journal.pone.0089068.g007
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patients and also indicate that enterocytes play an important role
as producers of this chemokine in the epithelial compartment.
In vitro Analysis of CXCL10 Induction in Duodenal Tissue
Viral infections (experimentally mimicked by poly I:C) and IL-
15 have been suggested as critical triggers for the damage
mechanisms that occur in the small intestinal mucosa during the
early stages of CD [20]. Therefore, we aimed to evaluate whether
IL-15 and poly I:C modulate the expression of CXCL10 in the
small intestine. To this end, duodenal biopsies from untreated CD
and non-CD controls were incubated in the presence or absence of
IL-15 and poly I:C. Interestingly, both innate immunity stimuli
caused a significant induction of CXCL10 expression in the
controls but not in celiac individuals (Figure 6).
Major Cell Populations Infiltrating the Small Intestinal
Mucosa in Active CD Express CXCR3
Because the number of Th1 cells is characteristically increased
in the duodenal mucosa in active CD and Th1 cells express
CXCR3, we hypothesised that the overproduction of CXCL10
may be involved in Th1 cell recruitment to the intestinal mucosa
in untreated CD. To this end, we analysed the presence of
CXCR3+ cells in duodenal biopsies from CD patients and controls
through confocal immunofluorescence microscopy and flow
cytometry.
Confocal microscopy studies showed an important infiltration of
CXCR3+ cells in the LP of untreated CD patients (Figure 7a).
The counting of CXCR3+ cells in the LP regions of duodenal
sections revealed an increased number of CXCR3+ cells in
untreated CD patients compared with controls (Figure 7b). CD
patients on a GFD presented numbers of CXCR3+ cells that were
similar to those found in control subjects. These results suggest that
gluten drives the active recruitment of CXCR3+ cells to the
duodenal mucosa in untreated CD patients and that GFD restores
the number of CXCR3+ cells to the baseline level that is found in
healthy tissues.
T lymphocytes and plasma cells are the two main populations
that infiltrate the LP in active CD. To evaluate whether this cell
recruitment process is a consequence of the CXCR3/CXCL10
signalling axis, cells isolated from duodenum samples were
subjected to flow cytometry analysis. LP CD3+ and CD4+ T
lymphocytes and CD138+ plasma cells were found to express
CXCR3 (Figures 7c and 7d). Altogether, these results highlight
the relevance of CXCL10 in the recruitment of the major
Figure 8. Infiltration of CXCR3+ cells in the intraepithelial compartment. a. Confocal immunofluorescence for CXCR3 was performed in
sections of duodenal biopsies. (i) Intraepithelial lymphocyte CXCR3+ cells in untreated CD patients are indicated by arrows. (ii). CXCR3+ cells were
rarely observed in the intraepithelial compartment in non-CD controls. The epithelium is delimited by a thin line. CXCR3 is shown in green, and nuclei
are shown in red. (Magnifications, 6306(i) and 10716 (ii)). b. Representative flow cytometric analysis from the epithelial compartment of a duodenal
sample of an untreated CD patient showing IELs (CD3+ CD103+) that express CXCR3.
doi:10.1371/journal.pone.0089068.g008
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lymphocytic infiltrating populations in the LP of untreated CD
patients.
Intraepithelial Lymphocytes Express CXCR3
Immunofluorescence confocal microscopy analysis showed
CXCR3+ cells in the intraepithelial compartment. Characteristi-
cally, these CXCR3+ intraepithelial cells were detected more
frequently in samples from untreated CD patients than in treated
CD or non-CD controls (Figure 8a). The analysis of the
epithelial compartment by flow cytometry showed that CD3+
CD103+ IELs express CXCR3 (Figure 8b). These findings
suggest that the production of CXCL10 by the epithelium is
responsible for the recruitment of CXCR3+ IELs, which are
characteristically increased in untreated CD.
Discussion
Gluten-specific CD4+ Th1 cells, which abundantly produce
IFNc, play a central role in tissue damage in CD enteropathy. Th1
cells and plasma cells are the two main populations that infiltrate
the small intestine mucosa in untreated CD patients. In addition,
CD8+ T cells, which may exert cytotoxic functions similarly to c/d
T cells, are also expanded preferentially in the intraepithelial
compartment of the celiac mucosa [1]. However, the mechanism
through which immune cells arrive at the small intestine mucosa in
CD enteropathy is not completely understood. Our results
demonstrate that the CXCL10/CXCR3 chemokine axis plays a
major role in immune cell recruitment in the inflamed intestinal
mucosa of CD patients as a result of gluten insult.
The chemokine receptor CXCR3 is characteristically expressed
in Th1 cells but is also highly expressed in innate lymphocytes,
such as NK cells and NKT cells, and in cytotoxic T cell and B cells
[12,13,21]. CXCR3 and its ligands (CXCL9, CXCL10, and
CXCL11) are undoubtedly linked to the Th1 pattern and
constitute an inflammatory pathway that coordinates the immune
responses at sites of infection and inflammation. In activated T
cells, CXCR3 expression is also important for the amplification of
IFNc-mediated recruitment into peripheral sites during infection
and in autoimmunity [5].
CXCL10, CXCL9, and CXCL11 are differentially expressed in
different pathological conditions, which suggests that these ligands
have no redundant biological functions [14,22]. In fact, different
studies have revealed that CXCL10 plays a unique and important
role in imprinting a pattern for the subsequent development of
autoimmunity [23,24]. In transgenic mice, the overexpression of
CXCL10 in the pancreas induces a rapid recruitment of effector
CD4+ and CD8+ T cells and accelerates the progression of type I
diabetes [25]. Thus, CXCL10 can also act as a bystander effector
that expands an autoaggressive immune response, which may
result in autoimmune disease.
In agreement with findings in other chronic inflammatory
conditions, such as type I diabetes [15], systemic sclerosis [19], and
autoimmune thyroiditis [26], we found that the CXCL10 serum
levels are significantly increased in untreated CD patients. Given
the massive production of CXCL10 that was observed in the small
intestine mucosa during active CD, we hypothesise that the small
intestine may be the main source of circulating CXCL10 in
untreated patients. In addition, the presence of high levels of this
proinflammatory chemokine in untreated patients suggests that
circulating CXCL10 can be considered a biomarker for CD.
Further evaluation using many samples is required to determine
the efficacy of this determination as a complementary test in the
diagnosis and the follow-up of CD patients. Determination of
CXCL9 and CXCL10 in serum also deserves further attention in
order to evaluate whether serum levels of these chemokines
reproduce the changes of expression observed in duodenal tissue.
We showed that CXCL10 is actively produced in the small
intestine in untreated CD. Notably, the CXCL11 mRNA levels
were also increased in this group. In contrast, changes in CXCL9
expression were not observed. A gluten-free diet reduced the levels
of CXCL10 and CXCL11, which suggests that an active induction
of these chemokines is a consequence of gluten insult. Further-
more, the expression of both chemokines showed a significant
positive correlation in duodenal samples from CD patients and
controls. Because CXCL10 and CXCL11 have similar promoter
regions [14], these ligands may be induced by similar activation
pathways. CXCL10 and CXCL11 are strongly induced by not
only IFNc but also type I IFNs and to a slight extent by TNFa
[14]. To evaluate whether these cytokines are linked to the
expression of the CXCR3 ligands in the small intestine mucosa,
we assessed the expression of IFNc, IFNb, and TNFa in biopsy
samples from untreated and treated CD patients and non-CD
controls. As expected, higher IFNc expression was observed in the
small intestine of untreated CD patients. We showed a positive
correlation between both CXCL10 and CXCL11 expression and
the IFNc levels in the duodenum of untreated CD patients, which
suggests that IFNc dominates the expression of these chemokines
during chronic inflammation in CD. Altogether, these results
suggest a differential regulation of CXCL9 in the duodenal
mucosa and, to some extent, the existence of common regulatory
pathways for CXCL10 and CXCL11 expression in the celiac
mucosa. In addition, CXCL10 and CXCL11 exhibit different
affinities to CXCR3 [14,27], and although CXCL10 binds
exclusively to CXCR3, CXCL11 binds to CXCR3 and also to
CXCR7 [28]. These differences may indicate that these two
chemokines have different functions. Further analysis is required
to clarify the differential roles of CXCL10 and CXCL11 in the
small intestine mucosa.
In agreement with the upregulation of CXCL10 that is
observed at the mRNA level, a massive expression of CXCL10
protein was found in the intestinal mucosa from untreated CD
patients. This pattern was due to a high number of CXCL10-
producing cells and a large amount of the chemokine secreted into
the extracellular space. Interestingly, the controls and treated
patients only presented scarce CXCL10-producing cells in the LP.
These findings indicate an active gluten-dependent production of
CXCL10 in CD patients.
In different tissues, CXCL10 has been reported to be expressed
by different cell types, such as CD4+ T cells, NK and NKT cells,
macrophages, dendritic cells, fibroblasts, and endothelial and
epithelial cells [7,17,29]. We then investigated the cellular sources
of CXCL10 in the duodenal mucosa and identified CD138+
plasma cells as CXCL10-producing cells in the LP from untreated
CD patients. In contrast, CD3+ (T cells) and HAM56+ (macro-
phages) did not express CXCL10. Considering the high number of
infiltrating CD138+ cells in the LP in active CD, plasma cells
would certainly be the main source of CXCL10 in the active
disease. In addition, since CD138+ plasma cells express CXCR3,
the CXCL10/CXCR3 chemokine axis would take a relevant role
in the recruitment of plasma cells into the LP. Interestingly,
CD138+ plasma cells produce locally anti-gliadin and anti-TG2
antibodies which play important roles in CD pathogenesis [30,31].
Interestingly, a confocal immunofluorescence analysis showed
that CXCL10 is also produced by enterocytes from the small
intestine in active CD patients. CXCL10 staining was not
observed in the epithelium of non-CD controls or treated CD
patients. Therefore, enterocytes are active producers of CXCL10
in the duodenum of CD patients during the inflammatory process,
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and this production of CXCL10 is triggered by gluten intake.
Although this study provides the first demonstration of the
production of CXCL10 by enterocytes in the small intestine,
similar results have been described in the colon [32,33], and
recently, the upregulation of CXCL10 was observed in colonic
enterocytes in inflammatory bowel diseases [9]. Altogether, these
findings indicate that enterocytes actively produce CXCL10 in a
chronic inflammatory setting.
The mechanisms during the early phase of CD pathogenesis
remain poorly understood. Viral infections have been suggested as
inducers of an inflammatory cascade in the small intestine mucosa
that can drive CD enteropathy in susceptible individuals [20]. In
addition, IL-15 is another important player during the initial
events. This cytokine participates in enterocyte damage by
potentiating the cytotoxic activity of intraepithelial lymphocytes,
among other effects [34]. Therefore, we aimed to evaluate
whether poly I:C (an experimental model of viral infections) and
IL-15 induce CXCL10 production in mucosal tissue. We found
that both treatments induce a strong and rapid increase in
CXCL10 expression in the intestinal mucosa of non-CD controls.
These results indicate that signalling pathways that are elicited
by poly I:C and IL-15, which lead to the increased production of
CXCL10, are operating fully in the small intestine mucosa. In
contrast, CXCL10 induction was not observed in the duodenal
samples from untreated CD patients. It is most likely that these
pathways are already overactivated in active CD, and conse-
quently, tissues with severe enteropathy cannot react to further
stimulation.
Previous studies conducted by Lammers et al. [35] using
immunohistochemistry showed the increased expression of
CXCR3 in the small intestine mucosa in untreated CD patients.
Importantly, in this work, confocal microscopy studies revealed a
marked increase in the number of CXCR3+ cells in the LP from
untreated CD patients. Disease remission, which was observed in
patients on a GFD, is accompanied by a reduction in the number
of CXCR3+ cells in the LP, and this decreased number is similar
to the numbers found in non-CD controls. In addition, CXCR3+
intraepithelial cells were more frequently found in the mucosa
from untreated celiac patients than in non-CD controls. There-
fore, the finding that enterocytes produce CXCL10 during active
CD may explain the characteristic increase in IELs that is
observed in untreated CD. Flow cytometry analysis demonstrated
that all cell populations that constitute the hallmark of CD
enteropathy, e.g., plasma cells and T cells in the LP and IELs,
express CXCR3.
To the best of our knowledge, this study provides the first
demonstration of the expression of CXCR3 and its ligands in the
small intestine. Our findings strongly suggest an active role for the
CXCR3/CXCL10 axis in the pathogenesis of CD and a direct
link between gluten ingestion and the activation of this axis.
CXCL10 is actively produced in both the LP and the epithelium
of the small intestine mucosa. Importantly, this chemokine was
found to be also induced by proposed relevant innate stimuli in
CD pathogenesis, including dsRNAs and IL-15 [20]. Consequent-
ly, the induction of CXCL10 may occur at two different stages of
the disease. Initially, innate immunity activation causes CXCL10
induction, and this induction can be further increased by the
presence of IFNc during the chronic phase. In addition, we
demonstrated that the major cell populations that infiltrate the
small intestine mucosa in untreated CD express CXCR3.
Therefore, the CXCR3/CXCL10 axis is not only involved in
the recruitment of the critical cellular players responsible for
mucosal damage in active CD, including Th1 cells and IELs, also
may play a role in the initiation and perpetuation of the
inflammatory process.
Supporting Information
Figure S1 The correlation of CXCL11 mRNA expression
with IFNc and IFNb mRNA levels in duodenal samples
from untreated CD patients and non-CD controls was
analysed. IFNc was positively correlated with CXCL11
expression in untreated celiac patients (r = 0.5354, p = 0.0048)
but not in non-CD controls (r = 0.0766, p = 0.7159). The analysis
between IFNb and CXCL11 expression in celiac patients did not
show a significant correlation (r = 0.2945, p = 0.1442). In contrast,
IFNb was positively correlated with CXCL11 in the control group
(r = 0.6061, p = 0.0013). Linear regression analysis, Pearson’s
coefficient, F-test.
(TIF)
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